TECregen
Basel
About TECregen
TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $12.5M
- Funding stage: Seed
- Last round: Seed (Jan 2026)
- Website: tecregen.com
- Phone: +41 61 633 22 41
Industries & Categories
Biotechnology, Manufacturing, Product Research
Social Profiles
Canonical: https://fsome.com/organization/tecregen-5449 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.